Boehringer Ingelheim Seeks Summary Judgment in IRA Lawsuit
Boehringer Ingelheim (BI) has filed a motion for summary judgment in its case against HHS objecting to the Inflation Reduction Act’s (IRA) drug price negotiation program, claiming that the undisputed material facts entitle BI to judgment as a matter of law.
Source: Drug Industry Daily